This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Michael Tesar, Ph.D.
Research Program Head at Affimed


Michael joined Affimed as Research Program Head in 2016. He is responsible for the development of tetravalent bispecific immune cell engagers based on Affimed’s proprietary ROCK® antibody platform. Prior to Affimed, he held positions at MorphoSys and Pierre Fabre as group leader in antibody discovery and preclinical development. He graduated from the University of Stuttgart in 1990 and conducted his Ph.D. research at the former Federal Research Center for Virus Diseases of Animals in Tübingen. After several years of post-doctoral training at the University of Utah and California he joined the Helmholtz Center for Infection Research in Braunschweig. Over the course of his career, Michael has developed a deep expertise in antibody discovery up to clinical development.

Agenda Sessions

  • Redirected Optimized Cell Killing (ROCK®): A Multispecific Antibody Platform For Innate Immune Cell Engagement